United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue sere

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with an ics in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, as monotherapy (without ics) increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of an ics is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ics. do not use serevent diskus for patients whose asthma is adequately controlled on low- or medium-dose ics. pediatric and adolescent patients available data from controlled clinical trials suggest that laba as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent pati

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol;   - powder for inhalation - 50 mcg/dose - active: salmeterol xinafoate 72.5ug equivalent to 50 µg salmeterol   excipient: lactose monohydrate - serevent is indicated for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in adults and children who are receiving inhaled or oral corticosteroids. serevent should be used only as an adjunct to corticosteroids in the management of asthma. serevent should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation) - inhalation, powder for - excipient ingredients: lactose monohydrate - indications as at 5th october 1995: long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma), in patients aged four years or more who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed by occasional use of short-acting inhaled beta 2 agonists. indication as at 13th january 1997 - adults: salmeterol is suitable for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma), in patients who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed by occasional use of short-acting inhaled beta-2 agonists. salmeterol also provides long-lasting (12 hours) bronchodilation for the reversible component of airways obstruction due to chronic obstructive pulmonary disease (copd). children aged 4 years and over: long-term regular treatment of reversible airways obstruction

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - salmeterol xinafoate - pressurised inhalation suspension - 25 microgram - selective beta-2-adrenoreceptor agonists - selective beta-2-adrenoreceptor agonists - it is indicated for the regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. serevent is also indicated in the prevention of exercise-induced asthma

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salmeterol as xinafoate - suspension for inhalation - salmeterol as xinafoate 25 mcg/actuation - salmeterol - asthma:serevent is indicated for the regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. serevent is also indicated in the prevention of exercise-induced asthma.chronic obstructive pulmonary disease (copd):serevent is indicated in the treatment of patients with copd.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 36.3ug equivalent to salmeterol 25 µg/dose;   - aerosol inhaler, metered dose - 25 mcg/dose - active: salmeterol xinafoate 36.3ug equivalent to salmeterol 25 µg/dose   excipient: norflurane

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salmeterol as xinafoate - powder for inhalation - salmeterol as xinafoate 50 mcg - salmeterol - salmeterol - salmeterol is a selective beta-2-agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (copd).in asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol - inhalation powder, pre-dispensed - 50 microgram(s) - selective beta-2-adrenoreceptor agonists; salmeterol

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - salmeterol xinafoate - pressurised inhalation, suspension - 25 microgram(s) - salmeterol